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Objectives: Attention-deficit/hyperactivity disorder (ADHD) can have a significant 
negative impact on health outcomes in adults. This study was designed, in part, to 
determine the functional outcomes and health care utilization of adult psychiat-
ric outpatients with ADHD in several European countries. MethOds: This was a 
multinational observational study. All eligible outpatients (excluding patients with 
any psychotic disorder) from a variety of outpatient settings were invited to partici-
pate. ADHD diagnosis was established with the Diagnostic Interview for ADHD in 
Adults (DIVA) based on the Diagnostic and Statistical Manual of Mental Disorders, 
5thEdition. All patients were further evaluated with the Sheehan Disability Scale 
(SDS) and the EuroQol-5 Dimensions (EQ-5D) questionnaire, which was also used 
to assess anxiety/depression. Results: Of 5662 patients approached, 2284 (40.3%) 
enrolled, of whom 1986 patients (87.0%) completed the study. Patients were 17 to 
72 (median= 42) years of age, and the majority were women (58.8%). Based on the 
DIVA, 17.4% (95% CI 15.7%-19.0%) of patients were diagnosed with ADHD. Patients 
with ADHD had moderate to severe overall impairment (mean SDS total score 18.9 
[SD= 6.6, n= 348] versus 11.6 [SD= 8.6, n= 1659] in patients without ADHD). On the 
EQ-5D, a majority of patients with ADHD indicated having problems performing 
their usual activities (66.2% versus 41.2%) and many reported being “extremely 
anxious or depressed” (24.6% versus 16.0%). However, compared to patients without 
ADHD (n= 1660), patients with ADHD (n= 349) were less often prescribed antide-
pressants (57% versus 71.9%). The proportions of patients who visited a primary 
care physician, psychiatrist, or psychotherapist during the previous 6 months were 
similar between the 2 groups. cOnclusiOns: Adult psychiatric outpatients with 
ADHD in our sample reported more overall functional impairment and psychiatric 
comorbidities compared to outpatients without ADHD. The use of medical resources 
was similar between the 2 groups.
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Objectives: To determine the cost-effectiveness of atypical long-acting injectable 
(LAI) antipsychotics in treating relapsed chronic schizophrenia from the viewpoint 
of the Finnish National Health Service. MethOds: A 1-year decision tree was 
adapted for use with patients in relapse, guided by an expert panel. Drugs included 
available atypical long-acting antipsychotics: paliperidone (PP-LAI), risperidone 
(RIS-LAI), olanzapine (OLZ-LAI) and aripiprazole (ARI-LAI). Rates of adherence, 
success, relapse and hospitalization were taken from the literature. Prices were 
obtained from standard lists and expressed in 2014 euros: drugs, psychiatrists/
physicians, psychiatric nurse, inpatient and outpatient hospital care. Outcomes 
included expected cost/patient treated, QALYs, rates of re-hospitalization, emer-
gency room (ER) visits and days in relapse. The primary analysis was the incre-
mental cost per QALY. These preliminary results were tested with 1-way sensitivity 
analyses on important inputs. Results: Over the 1-year time horizon, PP-LAI 
had the lowest total cost of 34,446€ per patient, RIS-LAI cost 37,338€ , ARI-LAI cost 
37,433€ and OLZ-LAI cost 41,384€ . PP-LAI had the highest number of QALYs (0.686), 
followed by OLZ-LAI with 0.680, RIS-LAI with 0.674 and ARI-LAI with 0.671. PP-LAI 
also had the lowest rates of all negative outcomes. Re-hospitalization rates were 
10.1%, 12.5%, 12.4% and 12.2% for PP-LAI, RIS-LAI, ARI-LAI and OLZ-LAI, respec-
tively, Respective ER visits were 20.6%, 23.2%, 25.4% and 21.7%. Patients receiving 
PP-LAI experienced 224.0 relapse days, as opposed to 234.8 with RIS-LAI, 237.5 
with ARI-LAI and 234.8 with OLZ-LAI. In 1-way sensitivity analyses, costs were 
robust (required changes > 20%) against changes in drug price, primary rate of 
success, rates of relapse, dropouts and adherence. The driver of the model for 
all drugs was hospitalization, comprising from 70%-81% of the total cost; drug 
costs constituted 12%-22% and medical care 8%-15%. cOnclusiOns: PP-LAI was 
shown to have the lowest cost and best clinical outcomes, and hence should be 
the atypical LAI of choice.
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Objectives: Art therapy provides an alternative to standard forms of psychological 
therapy. We estimated the cost-effectiveness of group art therapy for people with 
non-psychotic mental disorders. MethOds: A de novo area under the curve model 
was constructed with the following assumptions that: the maximum treatment 
effect would be associated with the time at which treatment ended; there would 
be a linear increase in treatment effect, from zero at baseline to the time at which 
treatment ended; there would be a residual effect of treatment with a linear decline 
in benefit until there was zero benefit at 52 weeks; given the short assumed duration 
of benefit, discounting was not necessary. Two RCTs identified in an accompanying 
clinical review provided data from which EQ-5D values could be estimated via map-
ping allowing comparisons to be made of group art therapy with wait-list control 
and with group verbal therapy. Scenario analyses altering the cost per patient and 
the assumed residual benefit were conducted. Results: Art therapy compared 
with wait-list control had a mean cost per quality adjusted life year (QALY) below 
nance treatment of schizophrenia. MethOds: The schizophrenia Markov model 
developed by the National Institute for Health and Care Excellence (NICE) was 
adapted to the context of LAI antipsychotics. Effectiveness was measured through 
Quality-Adjusted Life Years (QALYs) and number of relapses. The economic anal-
ysis was conducted over a ten-year time horizon, including cost of managing 
stable schizophrenia, relapse and treatment-emergent adverse events (TEAEs). 
Probabilities of relapse, discontinuation due to adverse events, and due to other 
reasons came from a mixed treatment comparison of pivotal clinical trials; disu-
tilities associated to TEAEs and other non-drug-specific inputs came from various 
epidemiological sources. Results: AOM was associated with higher number of 
QALYs (7.26 vs 7.17, 7.18 & 7.19 for PP, RLAI and OP respectively) over a 10-year time 
horizon. Assuming a theoretical parity price between AOM and PP, the base case 
analysis showed that AOM was the dominant strategy as compared to RLAI, PP and 
OP. Deterministic sensitivity analyses confirmed these overall Conclusions, the 
main drivers of cost-effectiveness being both probability and cost of relapse. In the 
probabilistic sensitivity analysis, AOM demonstrated a higher probability of being 
cost-effectiveness than RLAI, PP and OP at a willingness to pay threshold of £20,000 
(52%, 89% and 90%, respectively). cOnclusiOns: Although model outcome may 
vary according to local data and settings, and assuming a theoretical parity price 
with PP, AOM was found to provide clinical benefits at lower total costs compared 
to other atypical LAI antipsychotics, showing its value in the maintenance treat-
ment of schizophrenia.
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Objectives: Aim to determine the most cost-effective threshold of depression 
severity above which to prescribe anti-depressants to patients, in England and 
Wales, presenting with depression and under consideration for anti-depressants. 
Also aim to evaluate the cost-effectiveness of a new trial of anti-depressants 
in a population of wider range of depression severity than in previous tri-
als. MethOds: Meta-regression of existing study results to estimate a propor-
tional treatment effect on depression severity, which is then extrapolated to a 
wider range of severity than in included trials. An economic model which con-
sists of a continuous outcome for the initial 12 weeks of treatment, followed by 
a Markov model with states for depression category and treatment. Treatment 
effects on Hamilton Depression Rating Scale (HAMD) were mapped to EQ5D. 
Expected value of partial perfect information (EVPPI) was used to determine an 
upper bound on the value of collecting ffurther evidence. Results: Patients on 
anti-depressants had an additional 12% (CrI 3-21%) decrease in 6-week HAMD 
versus placebo. Treating patients with a severity > 2 on HAMD had the highest 
probability (> 65%) of being cost-effective at £20,000 willingness-to-pay thresh-
old. However this assumes that the relationship with severity can be extrapo-
lated beyond the range of HAMD included in the systematic review. A short-term 
trial investigating the relation between treatment effect and severity and qual-
ity of life in depression patients had EVPPI= £67.7 million over a 10 year time-
horizon. cOnclusiOns: On the basis of available evidence, our model suggests 
it may be cost-effective to treat patients with lower severity of symptoms than 
have been included in the majority of existing RCTs. However, evidence of treat-
ment efficacy in those with low HAMD is lacking, and there is likely to be value in 
conducting a trial on this lower severity population.
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Objectives: To assess, from the perspective of national health insurance, the 
cost-effectiveness of psychosocial support plus nalmefene versus psychosocial 
support alone, for the treatment of adult patients with alcohol dependence who 
have a high drinking risk level, without physical withdrawal symptoms, and who 
do not require immediate detoxification. MethOds: A cost-effectiveness Markov 
model, originally developed for the Single Technology Appraisal by the National 
Institute for Health and Care Excellence of Nalmefene, was adapted to the Greek 
health care setting to evaluate the health effects and associated costs of compared 
therapeutic options. The model consisted of a short-term phase (1 year: based on 
clinical trials assessing nalmefene) and a long-term phase (2-5 years) evaluat-
ing patient progression and a second-line abstinence treatment option. Clinical 
inputs were derived from ESENSE1 (NCT00811720), ESENSE2 (NCT00812461) and 
SENSE (NCT00811941) clinical trials and epidemiological data from the national 
statistical authority and published literature. All direct costs with respect to treat-
ment of alcohol dependence and the management of alcohol-attributable harmful 
events were considered reflecting the year 2014. Results: Over a 5-year hori-
zon, the addition of nalmefene to psychosocial support led to the avoidance of 
3,071 alcohol-attributable diseases/injuries and 851 deaths per 100,000 patients. 
Nalmefene plus psychosocial support reduced the proportion of high-risk and 
very high-risk drinkers (23% versus 37% with psychosocial support alone) and 
increased the number of controlled drinkers (61% versus 45%). In the base-case, 
the nalmefene plus psychosocial support arm cumulated a 5-year incremental 
cost of € 160 and an incremental QALY of 0.024. The incremental cost-effectiveness 
ratio of € 1,928 was considerably low with respect to the decision threshold of 
€ 16,000 per QALY gained (equal to the GDP per capita of Greece). cOnclusiOns: 
Treatment with nalmefene is cost-effective in the Greek health care setting leading 
to significant reductions of alcohol dependent patients and alcohol-attributable 
harmful events.
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peridone. MethOds: Cost-utility analysis was performed using a Markov model. 
The primary outcome was ICER/QALY. Oral risperidone, oral paliperidone and 
long-acting risperidone were selected as comparators. The basic components of 
the model include probabilities of relapse, individual hazard ratios for non-com-
pliance by medication type and switch of treatment probabilities. Specific utili-
ties for each health state were considered. Among relevant costs, reflecting payer’s 
perspective, drug acquisition costs, monitoring costs, costs of relapses, follow-up 
care and adverse events were considered. Results: Long-acting paliperidone 
reached ICER of EUR 16,233/QALY compared to oral risperidone, EUR 15,058/QALY 
to oral paliperidone and EUR 335/QALY to long-acting risperidone. The robustness 
of the model was supported by one-way deterministic analysis and probabilistic 
sensitivity analysis, which gave stable results. Long-acting paliperidone was cost 
effective in 97% of the simulations compared to oral risperidone. Long-acting pali-
peridone treatment gained incremental 0.903 QALYs on average compared to oral 
risperidone. cOnclusiOns: The treatment of schizophrenia using long-acting 
paliperidone is associated with increased QALYs. It reduces incidence of adverse 
events, results in better prevention of relapses and can be considered a cost-effective 
treatment in the Czech Republic.
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Objectives: Switching to vortioxetine (a new antidepressant) after inadequate 
response to selective serotonin re-uptake inhibitor/serotonin–norepinephrine 
reuptake inhibitor (SSRI/SNRI) resulted in a significant and clinically relevant 
improvement versus agomelatine (REVIVE head-to-head clinical study) and also 
better efficacy over sertraline, venlafaxine and bupropion (indirect comparison). 
The aim of this study is to assess the Finnish cost-utility of vortioxetine versus 
these antidepressants in patients who switch due to inadequate response to 
previous treatments. MethOds: A one year cost-utility analysis was performed 
using a decision tree model for the second line and a Markov model for subse-
quent lines of MDD treatment. Undiscounted payer and societal perspectives were 
considered. Three health-states (depression, remission, recovery) and two treat-
ment phases (2-month acute, 6-month maintenance) were defined. The relative 
efficacy of antidepressants was derived from the REVIVE trial and indirect com-
parisons at 2 months. Efficacy in subsequent treatment steps was derived from the 
STAR*D study. Adverse events and their consequences were included and derived 
from REVIVE, indirect comparisons, literature and expert opinion. Utilities were 
derived from REVIVE and the literature using Finnish preference weights. Finnish 
costs in 2013/2014 value were considered. Sensitivity analyses were conducted to 
assess the robustness of the findings. Results: Vortioxetine was dominant from 
the payer’s and societal perspective versus all comparators. It was projected to 
result to QALY gain of 0.013, 0.017, 0.025 and 0.028, and € 223 (€ 1074), € 128 (€ 957), € 110 
(€ 720) and € 238 (€ 1390) direct (total) annual cost saving compared to agomelatine, 
bupropion, venlafaxine and sertraline respectively. These results were confirmed to 
be robust in several sensitivity analyses. cOnclusiOns: Vortioxetine dominated 
agomelatine, bupropion, venlafaxine and sertraline in Finland and appears to be a 
relevant treatment option for MDD patients who need a therapy switch.
PMH35
cosT-effecTiveness of PAliPeriDone PAlMiTATe versus oTHer 
AnTiPsycHoTics for THe TreATMenT of scHizoPHreniA in frAnce
Doutriaux A.1, Cognet M.2, Druais S.2, Lançon C.3, Samalin L.4, Levy P.5, Godet A.6, Guillon P.7
1Amaris Consulting, London, UK, 2Amaris, London, UK, 3Hopital Sainte-Marguerite CHU, 
Marseille, France, 4CHU Clermont-Ferrand, Clermont-Ferrand, France, 5University of Dauphine - 
Paris, Paris, France, 6Janssen Cilag, Issy-les-Moulineaux, France, 7Janssen, Issy-les-Moulineaux, 
France
Objectives: To estimate the cost-effectiveness of paliperidone palmitate (PLAI), 
a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared 
to the most common antipsychotic strategies in France. MethOds: A Markov 
model was developed to simulate the progression of a cohort of schizophrenic 
patients through four health states (stable treated, stable non-treated, relapse 
and death) and up to three lines of treatment. PLAI was compared to risperidone 
LAI (RLAI), aripiprazole LAI (ALAI), olanzapine LAI (OLAI), haloperidol decanoate 
(HLAI) and oral olanzapine (OO). Costs, quality-adjusted-life-years (QALYS) and 
number of relapses were assessed over five years based on three-month cycles, 
and discounted at 4%, from a health insurance perspective. Patients were sup-
posed to be stabilised after a clinical decompensation and entered the model into 
an initiation phase, followed by a relapse prevention phase in case of success. 
In the prevention phase, relapse rates were derived from hospitalisation risks 
based on French real-life data in order to capture the adherence effects. Safety 
and utility data were derived from international publications. Costs came from 
French health insurance databases and publications. Robustness of results was 
assessed through deterministic and probabilistic sensitivity analyses. Results: 
PLAI was the less costly LAI and associated with an incremental cost-effectiveness 
ratio (ICER) of € 1,988/QALY gained and € 2,267/relapse avoided versus OO. RLAI 
and PLAI were associated with the highest number of QALYs (ICER of € 2,421,386/
QALY gained between PLAI and RLAI). PLAI dominated all other LAIs in terms of 
relapse but OLAI. Nevertheless, PLAI was highly cost-effective versus OLAI (ICER of 
€ 1,575,217/relapse avoided). cOnclusiOns: This analysis is the first to assess the 
cost-effectiveness of antipsychotics based on French observational data. PLAI was 
found to be the least expensive LAI antipsychotic from French payer perspective. 
Oral therapies were less expensive but associated with lower levels of QALYs and 
more relapses compared to all atypical LAIs.
£6000 for all scenarios and a 100% probability of being cost-effective at a willingness 
to pay of £20,000 per QALY. Verbal therapy appeared more cost-effective than art 
therapy with a cost per QALY below £1000 but there was considerable uncertainty 
in the decision and a sizeable probability (20%) that art therapy was dominant. 
In neither comparison was the art therapy intervention similar to that employed 
in England and Wales, furthermore in the wait list comparison patients were not 
explicitly diagnosed with non-psychotic mental disorders. As such, the generalis-
ability of the results to practice in England and Wales is uncertain. cOnclusiOns: 
Art therapy appears cost effective versus wait-list but of uncertain value compared 
with verbal therapy. Confirmatory studies are required to allow more definitive 
statements to be made.
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cosT-effecTiveness of liTHiuM versus An ATyPicAl AnTi-PsycHoTic 
(AAP) useD To AugMenT TreATMenT wiTH A selecTive seroTonin 
reuPTAke inHibiTor (ssri) in TreATMenT resisTAnT DePression (TrD)
Edwards S.J., Nherera L., Trevor N., Wakefield V.
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Objectives: To estimate the cost-effectiveness of augmentation of SSRI antidepres-
sant therapy with either lithium or an AAP in TRD, defined as failure to respond to 
two or more antidepressants. MethOds: CENTRAL, EMBASE, MEDLINE, PsycINFO 
and NHS Economic Evaluation Database (NHS EED) were searched from inception 
to August 2011. Additional data were obtained from manufacturers. Systematic 
reviews of the economic and quality of life (QoL) literature were executed. Studies 
were assessed, independently by two reviewers, for quality against predefined cri-
teria. A de novo probabilistic economic model was developed to synthesise the 
available data on costs and clinical effectiveness from UK NHS perspective; time 
horizon 1-year (8 weeks of acute treatment and 10 months of maintenance treat-
ment). Results: Four economic evaluations (none directly addressing the review 
question) and 17 QoL studies were identified and summarised in narrative reviews. 
Model results indicate that augmentation of an SSRI with lithium dominates aug-
mentation with AAP (i.e. Results in cost savings of £905 per person per year and 
generates more health benefits, estimated to be 0.03 quality-adjusted life-years). 
However, sensitivity analyses showed that the model was highly sensitive to 
changes in acute treatment efficacy (response and remission) or discontinuation. 
The model was not sensitive to changes in other parameters. cOnclusiOns: Cost-
effectiveness analyses suggest that augmentation with lithium is less expensive 
and more effective than augmentation with AAP. However, the uncertainty in the 
clinical estimates of discontinuation and treatment response is reflected in the 
model results. An RCT comparing the two augmentation strategies, reporting rel-
evant outcomes, including QoL, is needed.
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coMPuTeriseD cogniTive beHAviour THerAPy for DePression 
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Objectives: Computerised cognitive behaviour therapy (cCBT) forms a core com-
ponent of stepped psychological care within primary care in the UK and other 
countries. However, the existing clinical effectiveness evidence for cCBT comes 
from developer-led trials and independent research is needed which evaluates the 
clinical and cost-effectiveness of cCBT. MethOds: A cost-effectiveness analysis 
was undertaken comparing two cCBT software packages, free-to-use MoodGYM 
and a commercial pay-to-use Beating the Blues (BtB), in addition to usual 
general practitioner care (UGPC), with UGPC alone, for the treatment of depressed 
adults. The analysis was based on data collected on the Randomised Evaluation of 
the Effectiveness and Acceptability of Computerised Therapy (REEACT). REEACT 
was a large (n= 691), pragmatic multicentre study, independently conducted in 
a primary care setting. Outcomes were assessed using EQ-5D and used to esti-
mate quality-adjusted life-years (QALYs). Resource use and costs were esti-
mated from a NHS and Personal Social Services perspective. Scenario analyses 
were performed to determine the impact on cost-effectiveness of alterna-
tive assumptions, and uncertainty was characterised using cost-effectiveness 
acceptability curves. Results: BtB was both more expensive and generated lower 
QALYs than UGPC alone (dominated) and MoodGYM yielded lower QALYs but at 
lower cost, resulting in an ICER of £6,933 per additional QALY for UGPC alone 
versus MoodGYM. UGPC alone was the most cost-effective intervention in the 
majority of scenario analyses, and the intervention most likely to be cost-effec-
tive at a £20,000 per QALY threshold (probabilities ranging across scenarios from 
0.545 to 0.619). cOnclusiOns: Our findings indicate that commercially-produced 
products were no more effective than free-to-use cCBT programmes. Importantly, 
neither BtB or MoodGYM appeared cost-effective compared to UGPC alone. Practice 
recommendations such as those offered by NICE and other countries supporting 
the use of cCBT within stepped models of care for depression will need to be 
reconsidered in light of these results.
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Objectives: The number of patients with schizofrenia in the Czech Republic 
amounts annually to approximately 126,000. Schizophrenia causes signifi-
cant increases in mortality, shortening life expectancy by 25 years compared to 
the general population which implies high disease burden. The aim was to esti-
mate the cost-effectiveness of long-acting paliperidone in the treatment with 
schizofrenia compared to oral risperidone, oral paliperidone and long-acting ris-
